首页 › 基金 › Defilade Capital Management, L.P. › OLMA
Defilade Capital Management, L.P. 对 OLMA 的持仓历史
OLEMA PHARMACEUTICALS INC · 医疗保健
Defilade Capital Management, L.P. 在 Q3 2026 的 13F 申报中披露持有 OLMA(OLEMA PHARMACEUTICALS INC)1,440,157 股,市值约 US$12.4M,约占其申报组合的 2.08%,在其申报持仓中市值排名第 23 位。 Defilade Capital Management, L.P. 最近 4 个申报季度中有 4 个季度披露了 OLMA 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Defilade Capital Management, L.P. 对 OLMA 的持仓演变
Defilade Capital Management, L.P. 于 Q4 2025 首次披露 OLMA 持仓:1,234,634 股(约 US$30.9M)。 在 4 次申报中,Defilade Capital Management, L.P. 2 次增持、1 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 1,440,157 股、市值约 US$12.4M,环比增持 515,399 股。。 持仓曾出现大幅变动:Q2 2026 减持约 39% (随后一个季度股价下跌 31%)、Q3 2026 增持约 56% (随后一个季度股价下跌 15%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 1.23M | $30.87M | 新进 |
| Q1 2026 | 1.50M | $22.43M | 增持 |
| Q2 2026 | 924.76K | $11.57M | 减持 |
| Q3 2026 | 1.44M | $12.44M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 OLMA 与 13F 数据
OLMA(OLEMA PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 28 只申报持有 OLMA,申报仓位最大的包括:Paradigm Biocapital Advisors LP (US$75.3M), Bain Capital Life Sciences Investors, LLC (US$61.2M), BVF INC/IL (US$45.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 OLMA 的基金
- Paradigm Biocapital Advisors LP 8.72M 股 · $75.35M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 7.09M 股 · $61.22M · Q3 2026
- BVF INC/IL 5.30M 股 · $45.76M · Q3 2026
- Siren, L.L.C. 4.86M 股 · $41.96M · Q3 2026
- Logos Global Management LP 3.21M 股 · $27.72M · Q3 2026
- Cormorant Asset Management, LP 1.75M 股 · $15.12M · Q3 2026
- Lightspeed Management Company, L.L.C. 1.36M 股 · $11.71M · Q3 2026
- KINGDON CAPITAL MANAGEMENT, L.L.C. 1.20M 股 · $10.37M · Q3 2026
更多关于 Defilade Capital Management, L.P.
常见问题
How long has Defilade Capital Management, L.P. held OLMA?
Defilade Capital Management, L.P. has disclosed OLMA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Defilade Capital Management, L.P.'s current position in OLMA?
As of Q3 2026, Defilade Capital Management, L.P. holds 1.44M shares of OLMA (OLEMA PHARMACEUTICALS INC), valued at $12.44M, representing 2.08% of its reported portfolio and ranking #23.
Has Defilade Capital Management, L.P. been buying or selling OLMA?
In the latest 13F filing (Q3 2026), Defilade Capital Management, L.P. increased its position in OLMA.
Which other funds hold OLMA?
Other major institutional holders of OLMA include Paradigm Biocapital Advisors LP, Bain Capital Life Sciences Investors, LLC, BVF INC/IL, among 28 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.